Molecular cloning and expression of Iranian Leishmania major pteridine reductase

Iranian Journal of Parasitology

Volumn 3, Issue 2, 2008, Pages 1-9

  Kheirandish, F ^a,b   Bandehpour, M ^a   Haghighi, A ^a   Mahboudi, F ^c   Mohebali, M ^d   Mosaffa, N ^a   Kazemi, B ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Enzyme activity; Leishmania major; Methotrexate resistance; Pteridine reductase

Indexed keywords

PROTOZOAL PROTEIN; PTERIDINE REDUCTASE 1; RECOMBINANT PROTEIN;

AGAR DIFFUSION; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; ENZYMATIC ASSAY; ENZYME ACTIVITY; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE EXPRESSION; GENE SEQUENCE; IRAN; LEISHMANIA MAJOR; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMASTIGOTE; PROTEIN PURIFICATION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

LEISHMANIA MAJOR; ORYCTOLAGUS CUNICULUS;

EID: 69749101981     PISSN: 17357020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Desjeux P. Leishmaniasis public health aspects and control. Clin Dermatol. 1996;14(5):417-23.
2. Beck JT, Ullman B. Nutritional requirement of wild-type and folate transport-deficient Leishmania donovani for pterins and folates. Mol Biochem Parasitol. 1990;43(2):221-30.
3. Scott DA, Coombs GH, Sanderson BE. Folate utilisation by Leishmania species and the identification of intracellular derivatives and folate-metabolising enzymes. Mol Biochem Parasitol. 1987; 23(2):139-49.
4. Morreira ES, Soares RM, Petrillo-Peixoto Mde L. Glucantime susceptibility of Leishmania promastigotes under variable growth conditions. Parasitol Res. 1995;81(4):291-5.
5. kaur k, Coons T, Emmett k, Ullman B. Methotrexate-resistant Leishmania donovani genetically deficient in the folate-methotrexate transporter. J Biol Chem. 1988;263(15):7020-8.
6. Cunningham ML, Beverley SM. Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy. Mol Biochem Parasitol. 2001;113(2):199-213.
7. Ellenberger TE, Beverley SM. Reductions in methotrexate and folate influx in methotrexate-resistant lines of Leishmania major are independent of R and H-region amplification. J Biol Chem. 1987;262(28): 13501-6.
8. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliare P. A randomized, placebo, controlled trial of a two-week regimen of aminoacidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg. 1995;53(2):648-51.
9. Nare B, Hardy LW, Beverley SM. The role of pteridine reductase 1 and dihyrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J Biol Chem. 1997;272(21):13883-91.
10. El Fadili A, Kundig C, Roy G, M Ouellette. nactivation of the Leishmania tarentolae pterin transporter (BT1) and reductase (PTR1) genes leads to viable parasites with changes in folate metabolism and hypersensitivity to the antifolate methotrexate. J Biol Chem 2004;279(18): 18575-82.
11. Wang J, Leblanc E, Chang CF, Papadopoulou B, Bray T, Whiteley JM, Lin SX, Quellette M. Pterin and folate reduction by the Leishmania tarentolae H locus short-chain dehydrogenase/reductase PTR1. Arch Biochem Biophys. 1997;342(2):197-202.
12. Schuttelkopf AW, Hardy LW, Beverley SM, Hunter WN. Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. J Mol Biol. 2005;352(1):105-16.
13. Hunter WN, Alphey MS, Bond CS, Schuttelkopf AW. Targeting metabolic pathways in microbial pathogens: Oxidative stress and anti-folate drug resistance in trypanosomatids. Biochem Soc Trans. 2003;31(3):607-10.
14. Hadigi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A and Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug resistant Leishmania tropica parasites. PloS Med. 2006;3(5):162.
15. Sambrook J, Russell DW. Molecular Cloning. A laboratory manual Vol 1, Cold Spring Harbor Laboratory Press; 2001.
16. Pherson MC, Moller MJ. PCR the Basic from Background to Bench. Bios Scientific Publishers; 2000. p. 9-21.
17. Hyone-Myong Eun. Enzymology primer for recombinant DNA technology. Academic Press; 1996. p. 345-488.
18. Chung CT, Niemela SL, Miller RH. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cell in the same solution. Proc Nat Acad Sci USA. 1989;86(7):2172-5.
19. Sanders PG, Easton AJ. cDNA cloning. In Grove J.M., Fox A and Morgan NL. editors. Genetic manipulation, Techniques and application. Blackwell Scientific Publication; 1991. p. 129-148.
20. Feliciello I, Chinali G. A modified alkaline lysis method for the preparation of highly purified plasmid DNA from Escherichia coli. Anal Biochem. 1993;212(2):394-401.
21. Bandehpour M, Seyed N, Shadnoosh M, Pakzad P, Kazemi B. Using recombinant Chlamydia Major Outer Membrane Protein (MOMP) in ELISA diagnostic Kit. Iranian Journal of Biotechnology. 2006; 4(4):239-244.
22. Singh N, Nagar S, Roy U, Agrawal SS, Agrawal S, Rastogi AK. Antigenic analysis of soluble fraction of Leishmania donovani by SDS-Polyacrylamide gel electrophoresis and immunoblotting. Indian J Exp Biol.1995;33:313-315.
23. Kumar P, Kothari H, Singh N. Overexpressoin in Escherichia coli and purification of pteridine reductase (PTR1) from a clinical isolate of Leishmania donovani. Protein Expr Purif. 2004;38 (2):228-36.
24. Cruz A, Beverley SM. Gene replacement in parasitic protozoa. Nature. 1990;348 (6297):171-3.
25. Cruz A, Coburn CM, Beverley SM. Double targeted gene replacement for creating null mutants. Proc Natl Acad Sci USA. 1991; 88(16):7170-4.
26. Sirawaraporn W, Sertsrivanich R, Booth RG, Hansch C, Neal, RA, Santi DV. Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2.4-diaminopyrimidines. Mol Biochem Parasitol. 1988;31(1): 79-86.
27. Schuttelkopf AW, Hardy LW, Beverley SM, Hunter WN. Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. J Mol Biol. 2005;352(1):105-16.
28. Gangjee A, Yu J, McGuire JJ, Cody V, Galitsky N, Kisliuk RL, Queener SF. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. J Med Chem. 2000; 43(21):3837-51.
29. Kazemi B, Bandehpour M, Seyed N, Tohidi F, Mahboudi F, Abbaszadegan MR. Molecular Cloning, Expression and Enzymatic Assay of Iranian Lizard Leishmania Pteridine Reductase 1 (in press).